The Effect of Intravenous Injection of Emulsified Vitamin K, on the Hypoprothrombinemia Induced by Tromexan
1953; Massachusetts Medical Society; Volume: 248; Issue: 2 Linguagem: Inglês
10.1056/nejm195301082480204
ISSN1533-4406
AutoresWilliam C. Van Buskirk, John S. Belko, Thomas J. Giovanniello,
Tópico(s)Vitamin K Research Studies
ResumoTROMEXAN (ethyl biscoumacetate; 3, 3′ carboxymethylenebis- [4-hydroxycoumarin] ethyl ester also known as B.O.E.A., D.E.A. and Pelentan) has been proved to be an effective agent for inducing hypoprothrombinemia. After synthesis of the drug in 1948 by Reinis and Kubik,1 many investigators reported favorable clinical results. Severe hemorrhages, however, have followed its use.2 3 4 Since Vitamin K1 has been shown to be of value in reversing the hypoprothrombinemia induced by Dicumarol,5 it seemed possible that it would prevent catastrophes resulting from Tromexan therapy. The purpose of the present paper is to report observations on this point.Materials and MethodsFor the purpose of . . .
Referência(s)